About Auris Medical (NASDAQ:EARS)
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EARS
CUSIPN/A
Phone41-41-729-7194
Debt
Debt-to-Equity Ratio-2.59%
Current Ratio1.52%
Quick Ratio1.52%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.36) per share
Price / Book-4.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-24,800,000.00
Net MarginsN/A
Return on Equity-747.29%
Return on Assets-91.38%
Miscellaneous
Employees24
Outstanding Shares6,120,000
Auris Medical (NASDAQ:EARS) Frequently Asked Questions
What is Auris Medical's stock symbol?
Auris Medical trades on the NASDAQ under the ticker symbol "EARS."
How were Auris Medical's earnings last quarter?
Auris Medical Holding (NASDAQ:EARS) issued its earnings results on Thursday, March, 22nd. The biotechnology company reported ($1.01) EPS for the quarter. View Auris Medical's Earnings History.
When is Auris Medical's next earnings date?
What price target have analysts set for EARS?
1 analysts have issued 12 month price targets for Auris Medical's stock. Their forecasts range from $5.00 to $5.00. On average, they expect Auris Medical's share price to reach $5.00 in the next year. View Analyst Ratings for Auris Medical.
Who are some of Auris Medical's key competitors?
Some companies that are related to Auris Medical include Cyclacel (CYCC), Xenetic Biosciences (XBIO), Ritter Pharmaceuticals (RTTR), Soligenix (SNGX), OHR Pharmaceutical (OHRP), RXi Pharmaceuticals (RXII), Onconova Therapeutics (ONTX), Acura Pharmaceuticals (ACUR), EpiCept (IMNP), Dare Bioscience (DARE), EyeGate Pharma (EYEG), Anthera Pharmaceuticals (ANTH), Bioblast Pharma (ORPN), Heat Biologics (HTBX), Apricus Biosciences (APRI), Cotinga Pharmaceuticals (COTQF), Orexigen Therapeutics (OREX) and Argos Therapeutics (ARGS).
Who are Auris Medical's key executives?
Auris Medical's management team includes the folowing people:
- Dr. Thomas Meyer Ph.D., Founder, Chairman, CEO & MD (Age 50)
- Mr. Hernan Levett, Chief Financial Officer (Age 42)
- Ms. Cindy McGee, Head of Investor Relations and Corp. Communications
- Ms. Andrea Braun-Scherhag, Head of Regulatory & Quality Affairs (Age 51)
- Ms. Michelle Aarts Ph.D., Adviser
Has Auris Medical been receiving favorable news coverage?
Media coverage about EARS stock has trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Auris Medical earned a news sentiment score of 0.07 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 45.59 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Auris Medical?
Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Auris Medical's stock price today?
One share of EARS stock can currently be purchased for approximately $1.44.
How big of a company is Auris Medical?
Auris Medical has a market capitalization of $8.87 million. Auris Medical employs 24 workers across the globe.
How can I contact Auris Medical?
Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]
MarketBeat Community Rating for Auris Medical (EARS)
MarketBeat's community ratings are surveys of what our community members think about Auris Medical and other stocks. Vote "Outperform" if you believe EARS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EARS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Auris Medical (NASDAQ:EARS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Auris Medical in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 247.22%. The high price target for EARS is $5.00 and the low price target for EARS is $5.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.00 | $5.00 | $4.50 | $4.50 |
| Price Target Upside: | 247.22% upside | 599.30% upside | 529.37% upside | 529.37% upside |
Auris Medical (NASDAQ:EARS) Consensus Price Target History
Auris Medical (NASDAQ:EARS) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Auris Medical (NASDAQ:EARS) Earnings History and Estimates Chart
Auris Medical (NASDAQ EARS) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2018 | | | | | | | | |
| 3/22/2018 | Q4 2017 | | ($1.01) | | | View | N/A |  |
| 11/28/2017 | Q3 2017 | ($0.20) | ($0.15) | | | View | N/A | |
| 8/10/2017 | 6/30/2017 | ($0.21) | ($0.12) | | | View | N/A | |
| 5/11/2017 | 3/31/2017 | ($0.14) | ($0.22) | | | View | N/A | |
| 3/14/2017 | 12/31/2016 | ($0.29) | ($0.16) | | | View | N/A | |
| 11/10/2016 | Q316 | ($0.28) | ($0.23) | | | View | Listen | |
| 8/18/2016 | Q2 2016 | ($0.26) | ($0.26) | | | View | N/A | |
| 5/11/2016 | Q116 | ($0.23) | ($0.26) | | | View | Listen | |
| 3/14/2016 | Q415 | ($0.29) | ($0.1620) | | | View | Listen | |
| 11/12/2015 | Q315 | ($0.28) | ($0.16) | | | View | Listen | |
| 8/19/2015 | Q215 | ($0.23) | ($0.36) | | | View | Listen | |
| 5/28/2015 | Q115 | ($0.22) | ($0.29) | | | View | Listen | |
| 3/19/2015 | Q4 | ($0.23) | ($0.17) | | | View | Listen | |
| 12/3/2014 | Q3 | ($0.24) | ($0.14) | | | View | N/A | |
| 9/15/2014 | Q2 2014 | ($0.34) | ($0.29) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Auris Medical (NASDAQ:EARS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Auris Medical (NASDAQ EARS) Insider Trading and Institutional Ownership History
Auris Medical (NASDAQ EARS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Auris Medical (NASDAQ EARS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Auris Medical Announces Early Repayment of Part of its Loan Facility
finance.yahoo.com - April 17 at 8:17 AM |
 | Published Research Shows Ceragenin CSA-131's Potent Efficacy against Candida auris, a New Serious Global Health ...
www.prnewswire.com - April 6 at 8:15 AM |
| This Morning's Technical Outlook on Biotech Stocks -- Auris Medical, Anthera Pharma, Aralez Pharma, and Aratana Therapeutics
www.prnewswire.com - April 3 at 8:11 AM |
| Blog Exposure - Actinium Announces Collaboration with Astellas Pharma
finance.yahoo.com - April 2 at 8:21 AM |
 | Auris Medical Holding (EARS) Reports Compliance with Nasdaq's Minimum Bid Price Requirement
www.streetinsider.com - March 30 at 8:10 AM |
 | Auris Medical (EARS) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 6:58 PM |
 | Auris updates on development activities; shares up 25%
seekingalpha.com - March 24 at 5:23 PM |
 | Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 22 at 5:45 PM |
| Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 22 at 5:45 PM |
| Auris reports 4Q loss
finance.yahoo.com - March 22 at 5:45 PM |
| Auris Medical Provides Business Update - GlobeNewswire (press release)
globenewswire.com - March 14 at 8:17 AM |
 | BRIEF-Auris Medical Holding AG - Shareholders Approved Merger Between Co And Auris Medical Newco - SEC Filing
www.reuters.com - March 13 at 7:26 PM |
| Auris Medical Holding (EARS) Says TACTT3 Clinical Trial with Keyzilen Did Not Meet Primary Endpoint
www.streetinsider.com - March 13 at 7:26 PM |
| Auris Medical Provides Business Update
finance.yahoo.com - March 13 at 7:26 PM |
| What Are The Drivers Of Auris Medical Holding AG’s (NASDAQ:EARS) Risks?
finance.yahoo.com - February 28 at 8:07 AM |
| Auris Medical to Host Key Opinion Leader Call Focused on Keyzilen® Tinnitus Program on March 5, 2018 - GlobeNewswire (press release)
globenewswire.com - February 27 at 8:09 AM |
| Auris Medical to Host Key Opinion Leader Call Focused on Keyzilen® Tinnitus Program on March 5, 2018
finance.yahoo.com - February 26 at 5:51 PM |
| Technical Perspectives on Biotech Stocks -- Argos Therapeutics, Array BioPharma, Aurinia Pharma, and Auris Medical - PR Newswire (press release)
www.prnewswire.com - February 22 at 8:12 AM |
| Contrasting Ariad Pharmaceuticals (ARIA) & Auris Medical (EARS)
www.americanbankingnews.com - February 9 at 3:26 PM |
| Auris Medical (EARS) Says New Data Highlights Superior Bioavailability of AM-125 Compared to Oral Betahistine
www.streetinsider.com - February 9 at 8:53 AM |
| Auris Medical Announces Extraordinary General Meeting of Shareholders
finance.yahoo.com - February 9 at 8:53 AM |
 | Auris Medical Reports New Data Highlighting Superior Bioavailability of AM-125 Compared to Oral Betahistine
feeds.benzinga.com - February 7 at 10:06 AM |
| Auris Medical Holding (EARS) Prices $5.5M Registered Direct Offering of Common Stock, Warrants - StreetInsider.com
www.streetinsider.com - January 31 at 8:43 AM |
| Reviewing Auris Medical (EARS) and Audentes Therapeutics (BOLD)
www.americanbankingnews.com - January 31 at 3:44 AM |
| Proteon Therapeutics (PRTO) versus Auris Medical (EARS) Head to Head Contrast
www.americanbankingnews.com - January 12 at 7:04 PM |
| Auris Medical (EARS) & Its Competitors Critical Review
www.americanbankingnews.com - January 9 at 7:32 AM |
| Auris Medical Provides Update on AM-111 Development Program - GlobeNewswire (press release)
globenewswire.com - January 5 at 9:53 AM |
| Auris Medical Provides Update on AM-111 Development Program
finance.yahoo.com - January 4 at 9:45 AM |
 | Be All Ears: Auris To Provide Update On AM-111 On Jan.4
www.nasdaq.com - January 1 at 9:42 AM |
| Auris Medical Holding AG (EARS) Short Interest Up 86.3% in December
www.americanbankingnews.com - December 31 at 4:22 AM |
| Auris Medical News Release - Auris Medical to Provide Update on Its AM-111 Hearing Loss Program on Thursday ... - GlobeNewswire (press release)
globenewswire.com - December 28 at 3:44 PM |
| Auris Medical News Release - Auris Medical to Provide Update on Its AM-111 Hearing Loss Program on Thursday, January 4, 2018
finance.yahoo.com - December 28 at 3:44 PM |
 | Global Vertigo Market: Industry Analysis & Outlook 2017-2021: Major Players are Auris Medical, Sensorion, Otonomy and Sound Pharmaceuticals - Research and Markets
www.businesswire.com - December 20 at 9:49 AM |
| Auris Medical (EARS) versus Its Rivals Head to Head Review
www.americanbankingnews.com - December 17 at 1:28 PM |
| Auris Medical Holding AG (EARS) Short Interest Down 31.3% in November
www.americanbankingnews.com - December 16 at 3:42 AM |
| Contrasting Auris Medical (EARS) & The Competition
www.americanbankingnews.com - December 14 at 5:40 PM |
| Who Really Owns Auris Medical Holding AG (EARS)?
finance.yahoo.com - December 8 at 5:00 PM |
| Pre-market Technical Scan on Biotech Equities -- Viking Therapeutics, RXi Pharma, Kitov Pharma, and Auris Medical - PR Newswire (press release)
www.prnewswire.com - December 4 at 5:05 PM |
| Mid-Afternoon Market Update: Dow Jumps Over 150 Points; Auris Medical Shares Plummet - Benzinga
www.benzinga.com - November 29 at 5:25 PM |
| Auris Medical Holding (EARS) Announces Top-Line Results from ... - StreetInsider.com
www.streetinsider.com - November 29 at 5:25 PM |
| Mid-Afternoon Market Update: Dow Jumps Over 150 Points; Auris Medical Shares Plummet - Nasdaq
www.nasdaq.com - November 29 at 9:54 AM |
| EARS Pinched By HEALOS Data, EGLT Does It Again, JAVELIN Gastric 300 Misses Mark - Nasdaq
www.nasdaq.com - November 29 at 9:54 AM |
| Auris Medical Reports Third Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - November 29 at 9:54 AM |
| [$$] Decibel Therapeutics, Regeneron Strike Deal for Hearing Treatments
finance.yahoo.com - November 29 at 9:54 AM |
| Edited Transcript of EARS earnings conference call or presentation 28-Nov-17 1:00pm GMT
finance.yahoo.com - November 29 at 9:54 AM |
| Auris Medical (EARS) Announces Quarterly Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - November 28 at 9:48 PM |
| Auris Medical Holding (EARS) Tops Q3 EPS by 3c
www.streetinsider.com - November 28 at 5:02 PM |
| UPDATE 2-Auris Medical shares plunge as deafness drug trial scrapped
www.reuters.com - November 28 at 5:02 PM |
| Here’s What Triggered Auris Medical Holding AG (EARS) Selloff
finance.yahoo.com - November 28 at 5:02 PM |
| Auris Medical Holding AG (EARS) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - November 28 at 11:14 AM |
Auris Medical (NASDAQ:EARS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Auris Medical (NASDAQ:EARS) Income Statement, Balance Sheet and Cash Flow Statement
Auris Medical (NASDAQ EARS) Stock Chart for Sunday, April, 22, 2018
Loading chart…
